Ann: March 2022 Quarterly Activities Report and Appendix 4C, page-35

I was asked if I should invest in Race oncology ( ASX: RAC ) as their shares are trading higher than Noxopharm and they have a similar path to Noxopharm in the sense that they are using a drug that did not pass a 3rd phase trial, My response is I don't give financial advice, All investment in development drug companies is a risk, you just need to evaluate the risks and make up your own decision that is suitable for your circumstances. For my own investment I always look at how much money I am prepared to lose that is not going to affect my life.

All things being equal Race is only at preclinical stage whereas Noxopharm is at phase 2 trial and closer to commercialisation as they will sell after phase 2 should there be positive results at the trial. And Noxopharm doesn't have one drug they have multiple opportunities to capitalise on their technology all information can be accessed on their website http://www.noxopharm.com

If you compare share prices as at 29/04/2020

Race share price at $2.28 on 159 million shares
Noxopharm share price at $0.30 on 292 million shares

Invest with open eyes